G. Jackson

The Advantages of FTD Drug Development ( Part 2 of FTD : The Next Therapeutic Frontier )

Robert V Farese, William T. Hu, J. Morris, 2013 .

Improvement of platelet counts in steroid-unresponsive idiopathic immune thrombocytopenic purpura after short-course therapy with recombinant alpha 2b interferon.

G. Summerfield, P. Carey, R. Finney, 1989, Blood.

SHORT-COURSE ALPHA-INTERFERON THERAPY IN SEVERE UNRESPONSIVE IMMUNE THROMBOCYTOPENIC PURPURA

P. Carey, A. Stark, G. Jackson, 1988, The Lancet.

EML4-ALK Variants: Biological and Molecular Properties, and the Implications for Patients

R. Bayliss, S. Yeoh, Sarah R. Sabir, 2017, Cancers.

alpha 2b interferon (see comments) thrombocytopenic purpura after short-course therapy with recombinant Improvement of platelet counts in steroid-unresponsive idiopathic immune

G. Summerfield, P. Carey, R. Finney, 2011 .

MYELODYSPLASIC SYNDROMES IN CHILDREN

G. Jackson, N. Bown, A. Cant, 1993 .

Guidelines on the management of acute myeloid leukaemia in adults

C. Craddock, D. Grimwade, G. Jackson, 2006, British journal of haematology.

Prevention of herpesvirus infections in renal allograft recipients by low-dose oral acyclovir.

G. Jackson, D. Packham, M. Maddux, 1985, JAMA.

The prevention of illness from rhinovirus infection by a topical interferon inducer.

E. D. Stanley, G. Jackson, M. Rubenis, 1974, The Proceedings of the Institute of Medicine of Chicago.